Home
Resources
Publications
[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]

[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]

Tao Jiang, Caicun Zhou

Zhongguo Fei Ai Za Zhi. 2015 Apr;18(4):240-4.

PMID: 25936889

Abstract:

Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth factor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another heat point in the molecular targeted therapy of NSCLC. c-MET amplification or high expression was deemed to another significant gene modification beyond EGFR and ALK. In the preclinical studies, HGF/c-MET inhibitors have showed the promising anti-tumor effect. Recently, some phase II/III clinical trials have proved that these inhibitors could improve the survival of patients with NSCLC. Hence we performed this review to elaborate the research progress of c-MET inhibitor in the treatment of NSCLC.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42415667	c-Met Kinase Inhibitor III			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: